Therefore, an importantstrategy for successful PD-1/PD-L1 blockade treatment lies in transformingthe TME from immunosuppressive to immune-active, which involves increasingthe expression of PD-L1 on tumor cells and enhancing the recruitmentand activation of T cells.8,9. The gene discussed is CD274; the disease is neoplasm.